Profile photo

Urologic Oncology With Christopher Wallis, MD, PhD, FRCSC

Urology

Dr. Wallis is a urologic oncologist at the University of Toronto and Mount Sinai Hospital/University Health Network. He completed his Society of Urologic Oncology-accredited fellowship training at Vanderbilt University Medical Center. His clinical work and research are focused on the care of patients with prostate, kidney, bladder, and testis cancer.

SUO 2023: Setting the Stage for the Annual Meeting

Hey everyone,

This year’s Society of Urologic Oncology (SUO) 2023 Annual Meeting, to be held in Washington, DC, is rapidly approaching. While there is plenty of great content to look forward to, 2 phase 3 trials in non-muscle invasive bladder cancer (NMIBC) stand out.

There has been a lot of exciting data in bladder cancer this fall. I want to highlight a few of the biggest studies and set the stage for the upcoming SUO meeting. Some focus on the metastatic space, but we’re rapidly seeing a migration of therapies first used in patients with advanced disease migrate forward into the localized and NMIBC space, so I think this information holds lots of promise for urologists.

In the coming messages, I’ll highlight data from this year’s SUO meeting, including the BOND-003 and ENVISION trials.

-c
Christopher JD Wallis, MD PhD FRCSC

Articles
  • Mashup Score: 0
    ESMO 2023 special: Prof. Powles shares positive KEYNOTE-A39 trial results - 1 year(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of walliscjd
      walliscjd

      Arguably the biggest, practice-changing data that has come out this year in bladder cancer is the EV-302 trial which compared enfortumab vedotin and pembrolizumab to combination chemotherapy (the current standard of care) as first-line treatment in advanced/metastatic bladder cancer. These data prompted an enormous audience response when presented by Dr. Tom Powles at ESMO 2023. In this linked interview, Dr. Powles provides an accessible accounting of the data from this study and its nuances.

  • Mashup Score: 0
    Highlights on 1L nivolumab + chemo for metastatic urothelial carcinoma: The CheckMate 901 study - 1 year(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of walliscjd
      walliscjd

      In the same disease space as EV-302, CheckMate 901 assessed a different treatment approach: led by Dr. Michiel van der Heijden, this trial compared standard combination chemotherapy to chemoimmunotherapy with the addition of nivolumab. While other studies assessing chemoimmunotherapy as first-line treatment in advanced bladder cancer have been negative, this study showed significantly improved survival in patients receiving nivolumab in addition to chemotherapy. Listen in here as the first author provides more details on this practice-changing trial.

  • Mashup Score: 0
    #ESMO23 Expert report on the management of patients with high-risk non-muscle invasive bladder cancer - 1 year(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of walliscjd
      walliscjd

      While it may seem like I spend a lot of time on studies in the metastatic space (which feel more in the realm of the medical oncologist), many of these therapies will rapidly become part of our armamentarium in the localized disease space. We saw this with the migration of nivolumab into the adjuvant space following cystectomy. In the discussion here, Dr. Jim Catto discusses novel treatment approaches in NMIBC which were presented at ESMO – namely, TAR-200 (intravesical slow-release gemcitabine), TAR-210 (intravesical slow-release erdafinitib), and, in THOR-2, a comparison of erdafinitib with intravesical chemotherapy in patients with BCG-refractory NMIBC.